Recent reporting from The New York Times highlights a potential paradigm shift in HIV treatment: a single infusion of broadly neutralizing antibodies (bNAbs) that could suppress the virus for years.
By targeting stable regions of the virus and stimulating the body’s natural immune response, these engineered antibodies offer a “vaccine-like” effect that may eventually replace the burden of daily antiretroviral pills.
While researchers must still navigate challenges like viral mutation and global accessibility, this breakthrough moves the medical community closer to a “functional cure,” where long-term remission is maintained without constant medication, significantly improving the quality of life and privacy for those living with the virus.
For more info visit: https://www.nytimes.com/search?query=HIV
